PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression..

Journal article

Breast cancer progression, treatment resistance, and relapse are thought to originate from a small population of tumor cells, breast cancer stem cells (BCSCs). Identification of factors critical for BCSC function is therefore vital for the development of therapies. Here, we identify the arginine methyltransferase PRMT5 as a key in vitro and in vivo regulator of BCSC proliferation and self-renewal and establish FOXP1, a winged helix/forkhead transcription factor, as a critical effector of PRMT5-induced BCSC function. Mechanistically, PRMT5 recruitment to the FOXP1 promoter facilitates H3R2me2s, SET1 recruitment, H3K4me3, and gene expression. Our findings are clinically significant, as PRMT5 depletion within established tumor xenografts or treatment of patient-derived BCSCs with a pre-clinical PRMT5 inhibitor substantially reduces BCSC numbers. Together, our findings highlight the importance of PRMT5 in BCSC maintenance and suggest that small-molecule inhibitors of PRMT5 or downstream targets could be an effective strategy eliminating this cancer-causing population.

Authors: Chiang, K; Zielinska, A; Shaaban, A; Sanchez-Bailon, M; Jarrold, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Cell Reports
• Volume: 21
• Issue: 12
• Pages: 3498-3513
• Publication date: 2017-12-01
• Acceptance date: 2017-11-28
• DOI: 10.1016/j.celrep.2017.11.096
• EISSN: 2211-1247
• ISSN: 2211-1247
• Pmid: 29262329
• Language: English
• Keywords: FOXP1; epigenetics; self-renewal; breast cancer stem cell; PRMT5; H3R2me2s; drug resistance; breast cancer; arginine methylation; histone methylation